China's drug regulator approved the metoprolol succinate sustained-release capsules produced by Beijing Centergate Technologies (SHE:000931) subsidiary Shandong Huasu Pharmaceutical.
The drug is indicated for hypertension, angina pectoris or chest pain, and heart failure, according to a Monday disclosure to the Shenzhen bourse.